ARiDA
ARiDA

Six Studios. One system.

Six Studios. One scientific and commercial decision system.

Target, Drug, Indication, Valuation, Portfolio and Patent Studios apply different methods to the same asset and decision context. Use one Studio for a focused question or carry the evidence into the next decision without rebuilding the case.

Studios are introduced through private enterprise engagements. Available methods depend on the decision, deployment configuration and permitted evidence.

Contact us
01

Target opportunity

Target Studio

Does this target deserve the next investment?

Assemble target identity, disease biology, mechanism, tractability, safety and clinical precedent. ARiDA shows which evidence strengthens the thesis, which evidence blocks it and what should be learned next.

Inputs

  • Target identity, pathway and disease scope
  • Mechanistic, genetic and translational evidence
  • Tractability, modality, safety and clinical precedent
  • Internal findings, decision thresholds and unresolved questions

Outputs

  • Target evidence and contradiction map
  • Tractability, safety and precedent assessment
  • Advance, defer or stop posture
  • Evidence gaps and next-experiment priorities
02

Asset decisions

Drug Studio

Should this asset advance, defer, stop, be licensed or be passed?

Keep molecular developability, mechanism, clinical evidence, safety, competitive analogues, regulatory context, IP evidence and business assumptions inside the same asset case.

Inputs

  • Canonical asset identity, modality, target and mechanism
  • Structure, assay and developability evidence when available
  • Clinical, safety, regulatory, competitive and IP evidence
  • Stage gates, risk vetoes, transaction terms and business assumptions

Outputs

  • Asset 360 decision case
  • Developability, clinical and safety views
  • Risk-veto and sensitivity analysis
  • Valuation-ready assumptions and cross-Studio handoffs
03

Expansion strategy

Indication Studio

Where should this asset go next?

Compare scientific admissibility, clinical feasibility, differentiation, economics and execution constraints without hiding a weak dimension inside one composite score.

Inputs

  • Asset, target, mechanism and candidate indication set
  • Target validation, pathway, assay, clinical and safety evidence
  • Trial feasibility, differentiation and execution constraints
  • Economics, weights, exclusions and sequencing assumptions

Outputs

  • Admissible indication shortlist
  • Biology and feasibility matrix
  • Per-indication value and attractiveness views
  • Priority, sequence and evidence-gap brief
04

Asset and portfolio value

Valuation Studio

What is the defensible value range, and what moves it?

Connect scientific and clinical assumptions to rNPV, Monte Carlo distributions, real options and value of information. Reviewers can inspect an assumption and rerun the affected case.

Inputs

  • Development stage, timing, costs and revenue assumptions
  • Scientific evidence and probability-of-success inputs
  • Market, regulatory, IP and deal assumptions
  • Correlation, scenario ranges and decision options

Outputs

  • Risk-adjusted value distribution
  • Downside, sensitivity and tornado views
  • Real-options and value-of-information analysis
  • Inspectable assumption set and valuation decision record
05

Capital allocation

Portfolio Studio

Which programs should receive capital now?

Evaluate assets against strategy, cash, capacity, shared scientific risk, timing and available options. Keep credible alternatives and dominated choices visible for the committee.

Inputs

  • Asset universe, strategy and decision horizon
  • Risk-adjusted values and scientific dependencies
  • Budget, capacity, timing and concentration limits
  • Options, constraints and committee preferences

Outputs

  • Portfolio risk and correlation view
  • Efficient frontier and allocation options
  • Scenario and constraint stress tests
  • Fund, defer, partner or stop decision brief
06

IP evidence

Patent Studio

Which IP evidence changes the business decision?

Connect patent-family, ownership, claim-theme, exclusivity and proceeding evidence to lifecycle, transaction and competitive questions. Patent Studio prepares evidence for business and counsel review. It does not provide legal opinions or clearance conclusions.

Inputs

  • Technology, asset, target and competitor scope
  • Jurisdictions, dates, assignees and family context
  • Patent, regulatory, proceeding and commercial evidence
  • Lifecycle, transaction or competitive decision question

Outputs

  • Patent-family and ownership map
  • Claim-theme and proceeding evidence tables
  • Exclusivity and loss-of-exclusivity context
  • Evidence brief for business and counsel review

Comparison

Start with the question the team must answer.

Primary Studio and common handoffs for six biopharma decision questions. A Decision Case may use more than one Studio.
Decision questionTargetDrugIndicationValuationPortfolioPatent
Does this target deserve the next investment?PrimaryHandoffHandoffHandoffHandoffNot a standard handoff
Should this asset advance, defer, stop, be licensed or be passed?Not a standard handoffPrimaryHandoffHandoffHandoffHandoff
Where should this asset go next?HandoffHandoffPrimaryHandoffHandoffNot a standard handoff
What is the defensible value range, and what moves it?Not a standard handoffHandoffHandoffPrimaryHandoffHandoff
Which programs should receive capital now?HandoffHandoffHandoffHandoffPrimaryNot a standard handoff
Which IP evidence changes the business decision?Not a standard handoffHandoffNot a standard handoffHandoffHandoffPrimary

Private enterprise engagements

Bring the team a decision worth working through.

Contact us